Clinical and experimental hepatology · 2026
Estrogen receptor β activation attenuates portal hypertension and restores mesenteric vascular reactivity in cirrhotic rats via β-arrestin-2/RhoA/ROCK pathway modulation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sun Long-Ci, Ji Lin-Hua, Zhang Bin, Wu Zhi-Yong
Аннотация
AIM OF THE STUDY: This study investigated estrogen receptor (ER) subtype-specific effects on vascular hyporeactivity in cirrhotic portal hypertension (PHT), focusing on RhoA/ROCK signaling and β-arrestin-2.
MATERIAL AND METHODS: Cirrhosis and PHT were established by subcutaneous injection of CCl4. Cirrhotic rats were administered three ER subtype selective agonists (PPT [ERα], DPN [ERβ], G1 [GPER]) or β-estradiol (E2) alone or in combination with selective antagonists (MPP [ERα], PHTPP [ERβ], G15 [GPER]). Portal pressure and mesenteric arteriolar reactivity to norepinephrine were assessed. Protein expression was analyzed by immunoblotting.
RESULTS: In cirrhotic rats, portal pressure was significantly elevated, and the dose-response curve of mesenteric arterioles to norepinephrine (NE) exhibited a rightward shift with reduced amplitude. Compared to cirrhotic rats, the CCl4 + E2 and CCl4 + DPN groups exhibited significantly reduced portal pressure and a leftward shift in the dose-response curve. The portal pressure was higher and the curve exhibited a rightward shift with reduced amplitude in group CCl4 + E2 + PHTPP, compare to group CCl4 + E2. Both portal pressure and the dose-response curve in the CCl4 + E2 + MPP and CCl4 + E2 + G15 groups remained comparable to the CCl4 + E2 group. Immunoblotting and densitometric analysis revealed that the intensity of β-arrestin-2 expression increased when cirrhosis and PHT developed. Compared with the CCl4 group, the intensity in the CCl4 + E2, CCl4 + DPN, CCl4 + E2 + MPP, and CCl4 + E2 + G15 groups decreased, while that in the CCl4 + PPT, CCl4 + G1, and CCl4 + E2 + PHTPP groups remained unchanged. No significant changes occurred in α1-AR, RhoA, ROCK-1, or moesin expression across groups.
CONCLUSIONS: ERβ activation improves vascular hyporesponsiveness in cirrhosis by modulating β-arrestin-2, suggesting that ERβ may represent a novel therapeutic target for cirrhosis and PHT.
MATERIAL AND METHODS: Cirrhosis and PHT were established by subcutaneous injection of CCl4. Cirrhotic rats were administered three ER subtype selective agonists (PPT [ERα], DPN [ERβ], G1 [GPER]) or β-estradiol (E2) alone or in combination with selective antagonists (MPP [ERα], PHTPP [ERβ], G15 [GPER]). Portal pressure and mesenteric arteriolar reactivity to norepinephrine were assessed. Protein expression was analyzed by immunoblotting.
RESULTS: In cirrhotic rats, portal pressure was significantly elevated, and the dose-response curve of mesenteric arterioles to norepinephrine (NE) exhibited a rightward shift with reduced amplitude. Compared to cirrhotic rats, the CCl4 + E2 and CCl4 + DPN groups exhibited significantly reduced portal pressure and a leftward shift in the dose-response curve. The portal pressure was higher and the curve exhibited a rightward shift with reduced amplitude in group CCl4 + E2 + PHTPP, compare to group CCl4 + E2. Both portal pressure and the dose-response curve in the CCl4 + E2 + MPP and CCl4 + E2 + G15 groups remained comparable to the CCl4 + E2 group. Immunoblotting and densitometric analysis revealed that the intensity of β-arrestin-2 expression increased when cirrhosis and PHT developed. Compared with the CCl4 group, the intensity in the CCl4 + E2, CCl4 + DPN, CCl4 + E2 + MPP, and CCl4 + E2 + G15 groups decreased, while that in the CCl4 + PPT, CCl4 + G1, and CCl4 + E2 + PHTPP groups remained unchanged. No significant changes occurred in α1-AR, RhoA, ROCK-1, or moesin expression across groups.
CONCLUSIONS: ERβ activation improves vascular hyporesponsiveness in cirrhosis by modulating β-arrestin-2, suggesting that ERβ may represent a novel therapeutic target for cirrhosis and PHT.